Alliancebernstein L.P. Sells 444,604 Shares of Amgen Inc. $AMGN

Key Points

• AllianceBernstein L.P. trimmed its stake in Amgen by 42.8% in Q3, selling 444,604 shares and retaining 594,786 shares (about 0.11% of the company) valued at $167.85 million; institutional investors now own roughly 76.5% of Amgen.
• Amgen recently beat quarterly expectations with $5.29 EPS (vs. $4.76 est.) and $9.87B revenue, set FY2026 guidance of 21.600–23.000 EPS, announced a quarterly dividend of $2.52 ($10.08 annualized, 2.8% yield), and carries an average analyst rating of Hold with a $354 price target.

Alliancebernstein L.P. cut its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 42.8% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 594,786 shares of the medical research company's stock after selling 444,604 shares during the quarter. Alliancebernstein L.P. owned approximately 0.11% of Amgen worth $167,849,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Lazard Asset Management LLC increased its holdings in Amgen by 102.2% during the 3rd quarter. Lazard Asset Management LLC now owns 39,156 shares of the medical research company's stock worth $11,050,000 after purchasing an additional 19,790 shares during the period. New England Asset Management Inc. lifted its holdings in shares of Amgen by 0.5% in the 3rd quarter. New England Asset Management Inc. now owns 21,480 shares of the medical research company's stock worth $6,062,000 after buying an additional 105 shares during the period. Integrity Wealth Advisors Inc. lifted its holdings in shares of Amgen by 85.3% in the 3rd quarter. Integrity Wealth Advisors Inc. now owns 6,949 shares of the medical research company's stock worth $1,950,000 after buying an additional 3,199 shares during the period. Raymond James Financial Inc. grew its position in shares of Amgen by 1.2% during the 3rd quarter. Raymond James Financial Inc. now owns 1,746,516 shares of the medical research company's stock worth $492,864,000 after buying an additional 20,888 shares in the last quarter. Finally, Amundi increased its stake in shares of Amgen by 4.6% during the third quarter. Amundi now owns 2,408,089 shares of the medical research company's stock valued at $708,267,000 after buying an additional 104,920 shares during the period. Institutional investors own 76.50% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Royal Bank Of Canada lifted their price objective on Amgen from $335.00 to $360.00 and gave the company an "outperform" rating in a report on Wednesday, February 4th. Barclays began coverage on shares of Amgen in a research report on Friday, February 20th. They set an "equal weight" rating and a $350.00 target price on the stock. Freedom Capital cut shares of Amgen from a "strong-buy" rating to a "hold" rating in a research report on Thursday, February 12th. Piper Sandler increased their price objective on shares of Amgen from $381.00 to $432.00 and gave the company an "overweight" rating in a research note on Wednesday, February 18th. Finally, Guggenheim upped their target price on Amgen from $305.00 to $347.00 and gave the stock a "neutral" rating in a report on Friday, February 6th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have given a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat.com, Amgen currently has an average rating of "Hold" and an average price target of $354.00.

Amgen Stock Performance

Shares of AMGN opened at $366.25 on Tuesday. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. The firm has a market cap of $197.43 billion, a PE ratio of 25.74, a P/E/G ratio of 3.63 and a beta of 0.45. Amgen Inc. has a 12 month low of $261.43 and a 12 month high of $391.29. The stock has a fifty day moving average price of $358.64 and a 200-day moving average price of $326.25.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. During the same period in the previous year, the business earned $5.31 EPS. The firm's revenue for the quarter was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities research analysts predict that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be issued a dividend of $2.52 per share. The ex-dividend date is Friday, May 15th. This represents a $10.08 annualized dividend and a dividend yield of 2.8%. Amgen's dividend payout ratio is 70.84%.

Amgen Company Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.